Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2026-06-04 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Share Issue/Capital Change Classification · 85% confidence The document is the Hong Kong Exchange (HKEX) Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts…on Movements in Securities,” which reports changes in authorised/issued share capital, treasury shares and share option schemes for the month ended 31 May 2026. It is a routine regulatory submission detailing capital movements rather than an annual or interim financial report. This clearly falls under announcements of share capital changes. Therefore, it should be classified as Share Issue/Capital Change (SHA).
2026-06-04 English
CHANGE OF DIRECTORS AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES
Board/Management Information Classification · 95% confidence The document is an official announcement regarding the proposed appointment and resignation of directors and changes in the composition of board committees for Transcenta Holding Limited. It details biographical information of incoming non-executive and independent non-executive directors, terms of appointment, resignations of existing directors, and committee reassignments. This fits squarely into the “Announcement of changes in the company's board of directors or senior management” category.
2026-06-04 English
VOLUNTARY ANNOUNCEMENT-TRANSCENTA REPORTS RECEIPT OF HICB OUT-LICENSING MILESTONE PAYMENT AND STEADY CDMO BUSINESS GROWTH
Regulatory Filings Classification · 82% confidence The document is a voluntary business update announcement by a Hong Kong listed company describing receipt of a milestone payment and CDMO business growth. It contains no actual financial statements or formal meeting materials, nor is it announcing share issues, dividends, or management director appointments as the primary focus. It is not an earnings release or regulatory certification but a general corporate update provided to investors. This fits the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-26 English
VOLUNTARY ANNOUNCEMENT-TRANSCENTA'S PARTNER INHIBRX REPORTS POSITIVE UPDATED CRC DATA FOR OZEKIBART AND ANNOUNCES U.S. BLA SUBMISSION FOR CHONDROSARCOMA
Regulatory Filings Classification · 34% confidence The document is a voluntary corporate announcement providing business updates on clinical trial results and regulatory submissions. It does not present financial statements, dividend notices, capital-raising activities, or board changes. It is not announcing the publication of a formal report, nor is it a transcript or investor presentation. No defined category fits these scientific and regulatory milestone updates except the general regulatory/miscellaneous fallback. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-21 English
POSTPONEMENT OF ANNUAL GENERAL MEETING AND CHANGE OF PERIODS OF CLOSURE OF REGISTER OF MEMBERS
Regulatory Filings Classification · 85% confidence The document is a stock exchange announcement regarding postponement of the Annual General Meeting and the change in closure dates of the register of members. It does not contain AGM materials or minutes (AGM-R), nor actual voting results (DVA), but rather is a general regulatory announcement to the market. It’s not a financial report, management changes, or a formal circular, but a regulatory filing announcement. Therefore, it falls under the miscellaneous Regulatory Filings category (RNS).
2026-05-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 100% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Transcenta Holding Limited. It includes information on authorized and issued share capital, share options, share incentive schemes, and confirmations related to compliance with listing rules. The document is a regulatory submission reporting changes in share capital and share movements for the month ended April 30, 2026. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory filing required by the exchange to disclose share capital movements and related confirmations. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and detail confirm it is not a brief announcement but a formal regulatory return.
2026-05-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.